Search

Charles River Laboratories International Inc

Deschisă

SectorSănătate

203.05 -0.19

Rezumat

Modificarea prețului

24h

Curent

Minim

199.96

Maxim

203.85

Indicatori cheie

By Trading Economics

Venit

2.9M

56M

Vânzări

-27M

1B

P/E

Medie Sector

592.3

78.892

EPS

2.43

Marjă de profit

5.529

Angajați

18,700

EBITDA

-23M

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-1.14% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.2B

10B

Deschiderea anterioară

203.24

Închiderea anterioară

203.05

Sentimentul știrilor

By Acuity

100%

0%

362 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 dec. 2025, 15:21 UTC

Câștiguri

Correction to Home Depot Outlook Headline on Dec. 9

23 dec. 2025, 23:54 UTC

Market Talk

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dec. 2025, 23:40 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 dec. 2025, 21:21 UTC

Achiziții, Fuziuni, Preluări

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dec. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

St Barbara to Hold Deposit in Escrow

23 dec. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dec. 2025, 21:19 UTC

Achiziții, Fuziuni, Preluări

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dec. 2025, 21:13 UTC

Achiziții, Fuziuni, Preluări

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dec. 2025, 20:16 UTC

Market Talk

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dec. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dec. 2025, 19:13 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dec. 2025, 18:58 UTC

Market Talk

Gold Has Another Record-Setting Day -- Market Talk

23 dec. 2025, 18:32 UTC

Market Talk

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dec. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

23 dec. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 dec. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

23 dec. 2025, 17:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dec. 2025, 16:21 UTC

Market Talk

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dec. 2025, 16:16 UTC

Market Talk

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dec. 2025, 16:15 UTC

Market Talk

Precious Metals Pare Gains -- Market Talk

23 dec. 2025, 16:03 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank: Closing Expected Around Mid-January

23 dec. 2025, 16:03 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dec. 2025, 16:02 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dec. 2025, 16:01 UTC

Achiziții, Fuziuni, Preluări

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dec. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dec. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Telefonica Doesn't Set Out Financial Details of Divestment

23 dec. 2025, 15:41 UTC

Achiziții, Fuziuni, Preluări

Telefonica: Deal Will Allow Focus on Core Markets

23 dec. 2025, 15:40 UTC

Achiziții, Fuziuni, Preluări

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dec. 2025, 15:19 UTC

Market Talk

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

-1.14% jos

Prognoză pe 12 luni

Medie 200.55 USD  -1.14%

Maxim 225 USD

Minim 170 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

362 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat